Dr. Deborah C. Mash is a Professor of Neurology (Emeritus) and Molecular and Cellular Pharmacology at the University of Miami School of Medicine. With over 25 years of continuous NIH funding from the National Institute on Drug Abuse, Deborah is a leading expert on ibogaine and the discoverer of its active metabolite, noribogaine. She secured FDA approval for the first clinical trial of ibogaine in the U.S. in 1993 and conducted research and clinical development studies at a substance abuse treatment center in St. Kitts from 1996 to 2005. In 2010, Deborah co-founded DemeRx to advance noribogaine’s clinical development and took on leadership of the company in 2017.
Chief Executive Officer and President, Board Member